Trastuzumab biosimilar (EirGenix/Sandoz)

Product Name :
Trastuzumab biosimilar (EirGenix/Sandoz)

Search keywords :
Trastuzumab

drugId :
null

Target Vo:
Receptor protein-tyrosine kinase erbB-2

Target Vo Short Name :
HER2

Moa_Name:
Receptor protein-tyrosine kinase erbB-2 antagonists

First Approval Country :
EU

First Approval Date Filter:
2023

Origin Company_Name :
Eirgenix Inc

Active Company_Name :
Eirgenix Inc

Active Indication_Name:
Breast Neoplasms

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Ret Antibody
Cdk2 Antibody
KAP1 Antibody: KAP1 Antibody (YA719) is a non-conjugated and Mouse origined monoclonal antibody about 89 kDa, targeting to KAP1 (4E1). It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human.

Author: Betaine hydrochloride

Related Posts